Discovery of Novel TrkA Allosteric Inhibitors: Structure-based Virtual Screening, Biological Evaluation and Preliminary SAR Studies

Jing Guo,Shuang Xiang,Jie Wang,Yang Zhou,Zuqin Wang,Zhang,Ke Ding,Xiaoyun Lu

DOI: https://doi.org/10.1016/j.ejmech.2021.114022

IF: 7.088

2021-01-01

European Journal of Medicinal Chemistry

Abstract:Tropomyosin receptor kinases A (TrkA) is a potential therapeutic target for the treatment of numerous tumor types and chronic pain. However, most of the reported TrkA inhibitors are ATP competitive pan-Trks inhibitors that lack subtype selectivity. A selective TrkA inhibitor may provide valuable therapeutic benefits. Here, we described the discovery of novel TrkA allosteric inhibitors by structure-based virtual screening. A promising hit (D5261, TrkA cell IC50 = 3.32 μM) was selected for further studies. The binding free energy between TrkA and D5261 was calculated. In addition, the preliminary structure-activity relationship (SAR) studies with D5261 were investigated. The results suggest that D5261 can be used as a starting point for development of TrkA allosteric inhibitors.